TRAILBLAZER-2: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer’s disease.
- 60 Years to 85 Years of age
- Gradual and progressive change in memory function reported by participants or informants for ≥ 6 months
- Have a study partner who will provide written informed consent to participate
- No contraindication to MRI or PET scans
Want to participate in a study?
Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.